ArticleScience advances2025
Bacteriophage immunotherapy with artificial antigen-directed immune labeling against bacterial infection.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Reversing Macrophage Immunometabolic Dysfunction in Prolonged Infections Via a Glutaminolysis-Fueled Restoration-Based Hierarchically Selective Therapeutic System.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Dual-Functional Biohybrid Nanorobot to Synergistically Eradicate Biofilm and Degrade Antibiotic Resistance Genes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting the PGRN-BMP Lysosomal Axis With NPs@PGRN Reverses Immunometabolic Dysfunction in Chronic Septic Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- When bacteriophages encounter macrophages during their journey through the human body.Frontiers in cellular and infection microbiology · 2026Review
- Metalloimmunotherapies: metal-driven regulatory networks in the immune microenvironment.Frontiers in immunology · 2026Review
- Diabetic foot osteomyelitis: pathological microenvironment and matching tailored treatment strategies.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophage therapy has been recognized as a promising anti-infection alternative, while its clinical therapeutic outcomes are compromised due to the development of bacterial resistance, ongoing host immune dysfunction at infection sites, and their failure to adequately revitalize host immunity. Here, we present a strategy for artificial antigen-directed immune labeling of bacteria, capitalizing on residual bacteriophage capsids on bacterial surfaces, which enable immune cells to achieve quicker bacterial recognition and clearance. Specifically, Mn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.